1-7 of 7
Michael Jeffers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg, Sant P. Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz, Masafumi Ikeda, Yuichi Ando, Wolfgang Wick, Joachim P. Steinbach, Michael C. Burger, Katharina Wenger, Ulrik Lassen, Kamalesh K. Sankhala, Cristiana Roggia, Isabelle Genvresse, Catya Munhoz, Christine Rentzsch, Susanne Reschke, Simon Langer, Markus Wagner, Stefan Kaulfuss, Charles Cai, Eleni Lagkadinou, Michael Jeffers, Carol Peña, Ghazaleh Tabatabai
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2723–2733.
https://doi.org/10.1158/1078-0432.CCR-20-4256
Published: 15 May 2021
View articletitled, Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Open the PDF for Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial

Marcia S. Brose, Martin Schlumbeger, Michael Jeffers, Christian Kappeler, Gerold Meinhardt, Carol E.A. Peña
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7370–7380.
https://doi.org/10.1158/1078-0432.CCR-18-3439
Published: 13 December 2019
View articletitled, Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial
Open the PDF for Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial

Andrew X. Zhu, Yoon-Koo Kang, Olivier Rosmorduc, T.R. Jeffry Evans, Armando Santoro, Paul Ross, Edward Gane, Arndt Vogel, Michael Jeffers, Gerold Meinhardt, Carol E.A. Peña
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (19): 4870–4879.
https://doi.org/10.1158/1078-0432.CCR-15-2883
Published: 02 October 2016
View articletitled, Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Open the PDF for Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

Ho Yeong Lim, Jeong Heo, Hye Jin Choi, Cheng-Yao Lin, Jung-Hwan Yoon, Chiun Hsu, Kun-Ming Rau, Ronnie T.P. Poon, Winnie Yeo, Joong-Won Park, Miah Hiang Tay, Wen-Son Hsieh, Christian Kappeler, Prabhu Rajagopalan, Heiko Krissel, Michael Jeffers, Chia-Jui Yen, Won Young Tak
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5976–5985.
https://doi.org/10.1158/1078-0432.CCR-13-3445
Published: 30 November 2014
View articletitled, A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
Open the PDF for A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, Diane P. Leffingwell, S. Gail Eckhardt, Lia Gore, Karl D. Lewis, Glen J. Weiss, Ramesh K. Ramanathan, Grace K. Dy, Wen W. Ma, Beth Sheedy, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li-Tain Yeh, Ronald L. Dubowy, Michael Jeffers, Prabhu Rajagopalan, Neil J. Clendeninn
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1232–1243.
https://doi.org/10.1158/1078-0432.CCR-12-3529
Published: 03 March 2013
View articletitled, Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Open the PDF for Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Kam Fai Tse, Michael Jeffers, Vincent A Pollack, Denise A McCabe, Melanie L Shadish, Nikolai V Khramtsov, Craig S Hackett, Suresh G Shenoy, Bing Kuang, Ferenc L Boldog, John R MacDougall, Luca Rastelli, John Herrmann, Michael Gallo, Gadi Gazit-Bornstein, Peter D Senter, Damon L Meyer, Henri S Lichenstein, William J LaRochelle
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (4): 1373–1382.
https://doi.org/10.1158/1078-0432.CCR-05-2018
Published: 17 February 2006
View articletitled, CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Open the PDF for CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. in another window
Journal Articles

Preclinical Characterization of CG53135 (FGF-20) in Radiation and Concomitant Chemotherapy/Radiation-induced Oral Mucositis

Enrique Alvarez, Edward G. Fey, Pascal Valax, Zachary Yim, Jeffrey D. Peterson, Medhi Mesri, Michael Jeffers, Matthew Dindinger, Nancy Twomlow, Ashwini Ghatpande, William J. LaRochelle, Stephen T. Sonis, Henri S. Lichenstein
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3454–3461.
Published: 05 September 2003
View articletitled, Preclinical Characterization of CG53135 (FGF-20) in Radiation and Concomitant Chemotherapy/Radiation-induced Oral Mucositis
Open the PDF for Preclinical Characterization of CG53135 (FGF-20) in Radiation and Concomitant Chemotherapy/Radiation-induced Oral Mucositis in another window